We are live on ! Find out more
SC

Stralem & Co Portfolio holdings

AUM $157M
1-Year Est. Return 4.29%
This Fund
S&P 500
This Quarter Est. Return
+7.31%
1 Year Est. Return
+4.29%
3 Year Est. Return
+25.48%
5 Year Est. Return
+55.56%
10 Year Est. Return
–
AUM
$337M
AUM Growth
-$2.19M
Cap. Flow
-$24.3M
Cap. Flow %
-7.21%
Top 10 Hldgs %
33.68%
Holding
47
New
1
Increased
9
Reduced
35
Closed
1

Top Buys

Rank Stock Value
1
MAR icon
Marriott International
MAR
+$906K
2
KO icon
Coca-Cola
KO
+$192K
3
IFF icon
International Flavors & Fragrances
IFF
+$158K
4
DE icon
Deere & Co
DE
+$101K
5
BMY icon
Bristol-Myers Squibb
BMY
+$89K

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.74M
2
MSFT icon
Microsoft
MSFT
+$1.35M
3
UNH icon
UnitedHealth
UNH
+$1.3M
4
V icon
Visa
V
+$1.22M
5
PFE icon
Pfizer
PFE
+$1.08M

Sector Composition

Rank Sector Weight
1 Healthcare 31.09%
2 Technology 13.51%
3 Financials 10.93%
4 Consumer Discretionary 9.41%
5 Utilities 9.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
META icon
26
Meta Platforms (Facebook)
META
$1.47T
$8.37M 2.49%
50,920
-3,100
-6% -$561K
EOG icon
27
EOG Resources
EOG
$75.1B
$8.28M 2.46%
64,920
-5,600
-8% -$681K
JNJ icon
28
Johnson & Johnson
JNJ
$629B
$8.09M 2.4%
58,515
-5,450
-9% -$724K
CELG
29
DELISTED
Celgene Corp
CELG
$7.67M 2.28%
85,693
-6,625
-7% -$585K
CB icon
30
Chubb
CB
$132B
$7.58M 2.25%
56,755
-1,700
-3% -$230K
BNY
31
Bank of New York Mellon
BNY
$111B
$7.16M 2.13%
140,370
-4,900
-3% -$258K
CVX icon
32
Chevron
CVX
$386B
$6.87M 2.04%
56,175
-3,150
-5% -$382K
KMI icon
33
Kinder Morgan
KMI
$70.7B
$6.86M 2.04%
387,165
-40,250
-9% -$719K
BMY icon
34
Bristol-Myers Squibb
BMY
$130B
$1.2M 0.36%
19,300
+1,500
+8% +$89K
KO icon
35
Coca-Cola
KO
$373B
$1.13M 0.33%
24,400
+4,200
+21% +$192K
FE icon
36
FirstEnergy
FE
$27.2B
$1.07M 0.32%
28,900
– –
COST icon
37
Costco
COST
$421B
$1.01M 0.3%
4,300
-400
-9% -$90.1K
IFF icon
38
International Flavors & Fragrances
IFF
$21.4B
$1M 0.3%
7,200
+1,200
+20% +$158K
ADP icon
39
Automatic Data Processing
ADP
$107B
$994K 0.3%
6,600
-900
-12% -$127K
AAPL icon
40
Apple
AAPL
$4.41T
$993K 0.29%
17,600
-800
-4% -$41.7K
NVDA icon
41
NVIDIA
NVDA
$5.43T
$955K 0.28%
136,000
+12,000
+10% +$78K
DE icon
42
Deere & Co
DE
$167B
$947K 0.28%
6,300
+700
+13% +$101K
MAR icon
43
Marriott International
MAR
$92.5B
$937K 0.28%
+7,100
New +$906K
ZBH icon
44
Zimmer Biomet
ZBH
$18.7B
$789K 0.23%
6,180
+309
+5% +$36.7K
A icon
45
Agilent Technologies
A
$41.9B
$776K 0.23%
11,000
+1,100
+11% +$72.8K
GILD icon
46
Gilead Sciences
GILD
$168B
$726K 0.22%
9,400
+700
+8% +$52.9K
LLY icon
47
Eli Lilly
LLY
$1.09T
– –
-11,200
Closed -$956K
1
2

Similar funds

LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return
BC
Blackstart Capital New York $151M AUM 14.01% 1-Year Est. Return
JT
Jump Trading Chicago, Illinois $150M AUM 17.61% 1-Year Est. Return
SCM
Stellar Capital Management Phoenix, Arizona $147M AUM 5.91% 1-Year Est. Return
HF
Hellman & Friedman San Francisco, California $169M AUM
SMFS
Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
CCM
Castine Capital Management Boston, Massachusetts $129M AUM 23.45% 1-Year Est. Return

Stralem & Co's Q3 2018 Portfolio in Review

As of Q3 2018, Stralem & Co held 47 positions worth $337M, down 0.65% from $339M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Stralem & Co withdrew a net $24.3M in Q3 2018, closing 1 position and reducing 35 holdings. Its most notable exit was Eli Lilly, an estimated $956K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 30% a quarter earlier, followed by Technology and Financials.

Against the trend, Stralem & Co opened a new position in Marriott International worth $937K.

  • Stralem & Co's largest Q3 2018 buy was Marriott International: 7,100 shares worth $937K.
  • Stralem & Co added most to Coca-Cola in Q3 2018, an estimated $192K increase.
  • Stralem & Co's biggest Q3 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $1.74M.
  • Stralem & Co fully exited Eli Lilly in Q3 2018, selling an estimated $956K.
  • Stralem & Co's ten largest holdings make up 34% of its $337M portfolio in Q3 2018.
  • Stralem & Co opened 1 new position and closed 1 in Q3 2018.
  • Stralem & Co's portfolio value fell 0.65% quarter-over-quarter to $337M.

Based on Stralem & Co's 13F filing for Q3 2018, filed 17 Oct 2018.